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Galectin-1 is one of the most important lectins to 
date participating in the malignant tumor development. 
With more and more data available on its expression in 
tumors it is already clear that this lectin is an important 
target for cancer diagnostics and treatment.
Described in the 1980s, galectin-1 was more exten-
sively studied in 1990s. Its first involvement in cancer 
was associated with cell adhesion [1]. Later on the lec-
tin was shown to induce apoptosis of activated T-cells 
[2], and experiments have confirmed [3] that cancer 
cells express galectin-1 also to protect themselves 
from immune response. Latest finding is a participation 
of galectin-1 in tumor angiogenesis as an angiogenic 
factor [4]. Galectin-1 participation in various cellular 
processes is well reviewed [5–7].
A purpose of this review was to summarize the data 
obtained to date on galectin-1 expression in human 
cancers and possibility of its use in diagnostics and 
prognosis of the disease outcome. The data is sum-
marized according to tumor origin. The tumor sites are 
listed according to the frequency of tumor occurrence 
published by American Cancer Society, the Centers for 
Disease Control and Prevention, the National Cancer 
Institute, and the North American Association of Cent-
ral Cancer Registries [8]. 
Prostate. Studies of two LNCaP prostate carci-
noma cell line variants as a model of androgen de-
pendent and independent prostate cancer showed 
that galectin-1 expression is increased in androgen 
independent LNCaP cell line variant [9]. Androgen 
dependent LNCaP cell line variant appeared to be sus-
ceptible to galectin-1 induced apoptosis [10]. Pre sence 
of core 2N-acetylglucose-aminyl transferase, the en-
zyme which catalyzes addition of polylactose-amine 
sequences crucial for galectin-1 binding to O-glycans 
on cell surface receptors was crucial for apoptosis of 
androgen dependent LNCaP cell line variant induced 
by galectin-1 [11]. Increased expression of galectin-1 
was observed in stroma of primary prostate carcinoma 
samples in comparison to stroma of normal prostate, 
and increased galectin-1 expression positively corre-
lated with a poor prognosis of disease outcome [12].
Endothelial cells of capillaries infiltrating to tumor 
stroma have strongly increased expression of galec-
tin-1 in comparison to endothelial cells of capillaries in 
adjacent normal stroma [13]. Hypothesis of the authors 
that carcinoma cells induce galectin-1 expression in en-
dothelial cells was confirmed by incubation of endothe-
lial cells with conditioned media from PC-3 or DU145 
prostate carcinoma cells, which significantly increased 
galectin-1 expression in endothelial cells. Adhesion 
of PC-3 prostate carcinoma cells to endothelial cells 
expressing galectin-1 was increased in comparison to 
endothelial cells not expressing galectin-1 [13].
Lung. Examination of 159 cases of lung cancer 
patient specimens for their capacity to bind galectin-1 
demonstrated that patients showing expression of galec-
tin-1 binding sites revealed a better prognosis than those 
lacking binding sites or showing a weak reactivity [14].
Galectin-1 protein expression was increased in BEAS 
2B (human normal lung epithelial cells) in comparison to 
A549 (human malignant lung epithelial cells) [15].
In studies of atypical adenomatous hyperplasia 
(AAP) of lung (suggested to develop to peripheral lo-
calized lung carcinomas) alveolar lining cells from AAP 
were found to express higher level of galectin-1 and 
galectin-1 binding sites. The cells formed spatial clus-
ters. AAP in general was characterized by increased 
vascularisation in comparison to normal tissues [16].
Galectin-1 expressing lung tumors where shown to 
have poorer prognosis than non expressing ones by 
Szoke T. et al. [17, 18].
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Reduced proliferation accompanied by downregu-
lation of galectin-1 was observed after treatment of 
a lung carcinoma cell line A549 with extract of fun-
gus Antrodia camphorata [19]. Galectin-1 was also 
identified among secreted proteins from A549 lung 
carcinoma cells [20].
Invasiveness of CL1-5 lung adenocarcinoma cell 
line was shown to correlate positively with a level of 
galectin-1 expression by the cell line [21].
Breast. Galectin-1 is expressed by MDA-MB-435 
human breast carcinoma cells and is accumulated in the 
contact site between MDA-MB-435 and human umbili-
qual endothelial cells suggesting the role for galectin-1 
in adhesion of the breast carcinoma cells [22].
Different breast cancer cell lines express galec-
tin-1 mRNA as it was shown by Lahm et al. [23]. The 
overexpresion of proto-oncogene receptor HER2/neu 
(Human Epidermal growth factor Receptor 2/ neuro-
glioblastoma) in immortalized human mammary lumi-
nal epithelial cells upregulated expression of 35 genes 
including galectin-1 gene [24].
Farnesylthiosalicylic acid (FTS), which blocks the 
binding of GTP-H-Ras(12V) to its membrane acceptor 
protein, galectin 1, blocks the functionality of Ras and 
the activity of mTOR [25]. FTS also effectively inhibits 
the proliferation of MCF-7 breast cancer cells in culture 
[25]. Since this agent blocks MAPK as well as mTOR, 
it may be useful for the prevention of adaptive hyper-
sensitivity and prolongation of the effects of hormonal 
therapy in breast cancer.
Galectin-1 expression was detected in both drug-
sensitive MCF-7 and drug-resistant MCF-7/AdrR cells 
[26]. Galectin-1 was present in the cytosol, on the 
surface of the cells and in the culture media.
Galectin-1 was shown to be a substrate of matrix 
metalloproteinase (MMP)-14 expressed by breast 
cancer cells [27].
In metastatic mammary adenocarcinoma LM3 
and MCF-7 cells galectin-1 expression is increased in 
response to treatment with TGF-beta (tumor growth 
factor beta) [28]. Galectin-1 was identified as a me-
tastasis associated protein in the studies of two clones 
of human breast carcinoma cell line MDA-MB-435 
with different metastatic potential [29]. Correlation 
between increased expression of galectin-1 in cancer 
associated stromal cells and tumor invasiveness was 
also shown [30]. Proteomic profiling of seven breast 
cancer cell lines (MDA-MB-231 (metastatic), HCC1428, 
AU565, MDA-MB-468, SK-BR-3, MCF7 and BT-474) 
in compari son to normal human mammary epithelial 
cell (HMEC) line demonstrated that galectin-1 is up-
regulated in the metastatic cell line MDA-MB-231 in 
comparison to the rest of the cancer cell lines studied 
[31].
Colon. Galectin-1 expression was much higher it the 
stromal cells of colorectal carcinomas than adenomas and 
normal tissue as was it shown by Sanjuan X. et al. [32].
Expression of galectin-1 and its binding sites was 
higher in mild dysplasias, severe dysplasias and invasive 
carcinomas of the colon than in normal cases [33]. From 
four cell lines (HCT-15, LoVo, DLD-1 and CoLo201), only 
CoLo201 expressed galectin-1 mRNA and protein. From 
the cell lines only DLD-1 was not able to bind galectin-1. 
Galectin-1 added to the media had no effect on growth 
of the cell lines. The level of galectin-1 expression was 
related inversely to the growth rate of HCT-15, LoVo, 
DLD-1 and CoLo201 cells xenografted in vivo into nude 
mice - the higher was the galectin-1 expression level, the 
lower was growth rate of the cells. The influence (inhibi-
tion) of galalectin-1 on migration of HCT-15, LoVo, and 
CoLo201 was also shown [33].
Patients with galectin-1 positive colon tumors on 
Dukes A (invasion into but not through the bowel wall) 
and Dukes B (invasion through the bowel wall but not 
involving lymph nodes) stages had shorter survival pe-
riods than those with galectin-1 negative colon tumors 
on the same stages [34].
Important role for galectin-1 in adhesion of colon 
cancer cell line with metastatic phenotype CoLo 201 
was demonstrated [35]. The regulation of adhesion was 
dependent on carbohydrate binding ability of galectin-1. 
MAPK and PLC inhibitors decreased the adhesion. Intra-
cellular galectin-1 overexpression induced apoptotic cell 
death in CoLo 201 cells, while exogenous galectin-1 was 
not able to induce apoptosis in these cells [35].
Galectin-1 expression is upregulated in KM12 hu-
man colon carcinoma cell line upon sodium butyrate 
treatment [36]. The treatment induces acquisition 
of differentiated phenotype by the cell line. There is 
an interesting observation that although HCT-116 
and HT-29 colon cancer cell lines express galectin-1 
mRNA, only HCT-116 cells express the protein [26].
Urinary tract, kidney. Bladder transitional cell 
carcinomas were examined for the level of expres-
sion of galectin-1 mRNA [37]. Higher grade tumors 
expressed significantly higher levels of galectin-1 
mRNA than low grade tumors or the cells of normal 
bladder. Western blot and imunohystochemical analy-
sis showed similar results on the protein level.
Galectin-1 expression is upregulated in bladder 
cancer tissue in comparison to normal bladder tissue 
as it was shown by Sheng K.H. et al. [38].
Galectin-1 mRNA is upregulated in cytoplasm of 
parenhimal cells of urothelial tumors, and upregulation 
correlates with tumor grading [39].
Lymphoid tissue. Treatment of diffuse large B cell 
lymphoma (DLBCL) cell line HBL-2 and Burkitt’s lympho-
ma cell line HBL-8 with neuraminidases, which remove 
sialic acid from the cell surface, enhances their adhesion 
to galectin-1 [40]. The sialation could have a clinical 
outcome since diffuse large B cell lymphoma patients 
with sialylated type of leuko-phytohemagglutinin (L-PHA) 
reactive oligosaccharides had a poor prognosis.
Upregulation of galectin-1 as well as galectin-1-
binding carbohydrates expression in cutaneous T 
cell lymphomas (CTCL) in comparison to pseudolym-
phoma and atopic dermatitis was demonstrated [41]. 
Chemotherapy with pegylated liposomal doxorubicine 
decreased the expression of galectin-1 and galectin-
1-binding carbohydrates in CTCL.
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CD7– cells of the early stages of cutaneous T cell 
lymphoma (Sezary syndrome) were resistant to 
galectin-1 induced cell death, what possibly led to 
their accumulation at the late stages of the disease 
[42]. Although SeAx/i CD7+ cell line was susceptible 
to galectin-1 induced apoptosis, CD7+ HH cell line 
was not susceptible to galectin-1induced apopotosis 
suggesting that altered glycosilation of CD7 was re-
sponsible for this [42]. It was shown that the basis for 
resistance to galectin-1 induced cell death in CD7+ HH 
cells from mucosis fungoides is in core 2 beta-1,6-N-
acetylglucosaminyltransferase (C2GnT-I) deficiency 
[43]. C2GnT-I is the enzyme, which creates core 2 
O-glycan ligands for galectin-1.
Galectin-1 was expressed in Hodgkin lymphoma 
(HL) cell lines L540, L1236, HDLM2, L428. 26 of 42 ca-
ses of classic HL were positive for galectin-1, whereas 
nodular lymphocyte predominant HL was negative 
for galectin-1 [44]. High expression of galectin-1 was 
associated with male gender, older patients, reduced 
CD8+ T cell infiltration at the tumor site, and an impaired 
latent membrane protein 1 and 2-specific CD8+ T-cell 
responses. Proliferation and interferon-gamma expres-
sion by Epstein — Barr virus-specific T cells was inhibi-
ted by exposure to recombinant galectin-1 in vitro.
Neoplastic Reed–Sternberg (RS) cells of classical 
Hodgkin lymphomas (cHL) overexpressed galectin-1. 
Galectin-1 was directly involved in maintenance of im-
munosuppressive microenvironment in cHL [3].
Galectin-1 is selectively expressed by malignant RS 
cells in > 90% of primary cHLs in contrast to diffuse 
large B-cell lymphoma, primary mediastinal large B-
cell lymphoma, and nodular lymphocyte-predominant 
Hodgkin lymphoma which do not express the lectin 
[45]. The anaplastic large cell lymphomas (ALCL) also 
express galectin-1.
Skin. Galectin-1 mediates A375 and A2058 mela-
noma cell lines adhesion to laminin in carbohydrate 
dependent fashion [46].
Blocking of galectin-1 expression in vivo stimulates 
antitumor immunity and promotes tumor rejection in 
a case of melanoma in mice [47].
Pancreas. Significantly higher level of galectin-1 
was detected in pancreatic cancer tissue stromal 
fibroblasts and extracellular matrix, than in normal 
pancreatic tissue [48]. Galectin-1 mRNA and protein 
levels were significantly higher in poorly differentiated 
tumors than in that of well/moderately differentiated. 
Pancreatic cancer metastases showed no galectin-1 
expression. Galectin-1 protein was upregulated in 
pancreatic ductal adenocarcinoma in comparison to 
normal pancreatic tissue [49].
Upper digestive tract. Galectin-1 was upregu-
lated in tongue carcinoma tissues compared to normal 
mucosa [50].
The lectin was overexpressed in the tumor-asso-
ciated stroma of the oral squamous cell carcinomas 
(OSCC) as well as the invasion front during early oral 
carcinogenesis [51]. During the metastasis significant 
galectin-1 expression was detected only at the tumor 
invasion front. It is suggested that galectin-1 upregula-
tion at the tumor invasion site might be a predictor of 
early metastasis in oral carcinogenesis.
Galectin-1 is upregulated in cancer-associated en-
dothelial cells in the specimens of OSCC in comparison 
to adjacent nontumor mucosa [52]. It was also demon-
strated that galectin-1 increased the proliferation and 
adhesion of endothelial cells (EC), and enhanced EC 
cell migration in combination with VEGF.
Invasivness of OSCC cell lines positively correlates 
with galectin-1 expression [21]. Decrease of galectin-1 
expression in most invasive HSC-3 cell line caused by 
siRNA to galectin-1, decreased invasiveness of the cell 
line. In contrary, overexpression of galectin-1 in poorly 
invasive OEC-M1 cell line increased invasiveness. It 
was also shown that in OSCC tissue galectin-1 was 
upregulated in metastatic lesions in lymph nodes in 
comparison to primary tumor sites.
Epithelial tissues in head and neck squamous cell 
carcinomas (HNSCC) exhibited lower amounts of 
galectin-1 and their respective binding sites than their 
corresponding normal counterparts [53].
Galectin-1 expression is upregulated and secretion 
to the media is induced by hypoxia in FaDu cells (cell 
line of a squamous cell carcinoma of the hypopha-
rynx) [54]. Staining of tumor tissues from 101 HNSCC 
patients showed correlation of expression of galec-
tin-1 and carbonic anhydrase IX (a hypoxia marker). 
Galectin-1 and CD3 (T cell marker) staining could be 
used in prognostic purposes. Three groups could be 
distinguished — favourable (negative to weak galec-
tin-1 staining and strong CD3 staining), intermediate 
(strong staining for both markers or negative to weak 
staining of both markers) and unfavourable (strong 
galectin-1 and negative to weak CD3 staining).
Serum galectin-1 levels are higher in patients with 
HNSCC and successful treatment reduces galectin-1 con-
tent in serum as it was shown by Saussez S. et al. [55].
Thyroid gland. Most aggressive and undifferen-
tiated anaplastic thyroid carcinomas consistently exhibi-
ted a marked increase of galectin-1 expression [56].
Thyroid malignancies of epithelial origin (i. e., papil-
lary and follicular carcinomas) and metastatic lymph 
nodes from a papillary carcinoma expressed high 
levels of galectin-1 [57]. Medullary thyroid carcinomas 
had weaker and variable expression of galectin-1. 
Benign thyroid adenomas and adjacent normal thyroid 
tissue expressed no galectin-1.
Concentration of galectin-1 was increased in the 
sera of patients with benign thyroid lesions in compari-
son to healthy individuals [58].
Stomach. Examination of transcription profiling of 
metastatic gastric cancer TMC-1 cells and the non-in-
vasive gastric cancer SC-M1 cell showed higher galec-
tin-1 expression in TMC-1 cells suggesting galectin-1 
as a metastasis marker in gastric cancer [59].
Brain, nervous system. High galectin-1 mRNA 
levels in glioma tissues and glioma cell lines was demon-
strated [60]. High galectin-1 protein content in glioma 
tissues was confirmed by immunohisochemistry.
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Galectin-1 expression is higher in astrocytomas, 
anaplastic astrocytomas, glioblastomas in comparison 
to pilocytic astrocytomas [61]. All glioblastoma cell 
lines examined contained galectin-1.
Expression of galectin-1 was shown in all studied 
human glioma types [62]. The level of galectin-1 ex-
pression correlated with the grade only in the group of 
astrocytic tumors. Patients with high-grade astrocytic 
tumors that had high level of galectin-1 expression, 
had shorter survival periods than those with low level 
of galectin-1 expression. In human glioblastoma xeno-
grafts, galectin-1 was preferentially expressed in the 
more invasive parts of these xenografts. The authors 
also showed that migration of U373 astrocytes was 
stimulated by galectin-1.
Immunohistochemical analysis of galectin-1 ex-
pression of human U87 and U373 glioblastoma xeno-
grafts from the brains of nude mice showed a higher 
level of galectin-1 expression in invasive  areas of the 
xenografts in comparison to the non-invasive areas 
[63]. Galectin-1 added to the culture media increased 
cell motility levels of human U87 glioblastoma cells.
Temozolomide (the standard treatment for glioma 
patients), increases galectin-1 expression in human 
Hs683 glioblastoma cell line, and the reduction of ga-
lectin-1 expression in these cells by siRNA increases 
the anti-tumor effects of temozolomide as well as the 
other chemotherapeutic agents [64].
Galectin-1 expression in the human glioblastoma 
multiforme cell lines positively correlated with migra-
tory abilities and invasiveness [65]. Analysis of human 
glioma samples  revealed that increased galectin-1 ex-
pression was associated with a higher tumor grade.
Ovary. Examination of galectin-1 expression in 
30 human epithelial ovary carcinoma samples by Wes-
tern and Northern blotting and by immunohistoche-
mistry showed that 95% of ovary carcinoma samples 
had higher galectin-1 mRNA level and 57% higher 
protein level in cancer epithelial cells in comparison 
to normal ovary [66]. Higher level of galectin-1 was 
detected by immunohistochemistry in stroma of car-
cinomas than in stroma of normal ovary. Galectin-1 
protein expression was detected in AZ364, SK-OV-3, 
and AZ224 but not in OVCAR-3, AZ419, and AZ382 
human ovary carcinoma cell lines. Conditioned media 
from AZ364, AZ224, OVCAR-3, AZ382 induced galec-
tin-1 expression in cultured 84BR fibroblasts. Positive 
influence of galectin-1 on above mentioned cell lines 
adhesion to laminin and fibronectin was also shown.
Liver. Galectin-1 expression was shown by immu-
nohystochemistry in intrahepatic cholangiocarcinoma 
(ICC) while no galectin-1 expression was seen in normal 
bile ducts [67]. ICC cells with higher galectin-1 expres-
sion level had higher proliferation rate. Galectin-1 was 
also strongly expressed in the cancerous stroma of ICC. 
Cholangiocarcinoma cell line, CCKS1 expressed galec-
tin-1 in the cytoplasm and secreted to the medium.
Galectin-1 mRNA was upregulated in primary he-
patocellular carcinomas in comparison to non tumor 
liver tissues [68].
Myeloid tissue. Galectin-1 is expressed in bone 
marrow samples of multiple myeloma patients. The 
lectin promotes survival of CD45RA– primary myeloma 
cells and myeloma cell lines, while reduces the viable 
cell number in CD45RA+ B cell lines [69].
Uterine, cervix. Galectin-1 expression is in-
creased in endometrial cancer cells in comparison to 
normal adjacent endometrium [70].
Galectin-1 expression in stromal cells adjacent to 
neoplastic endothelia in cervical neoplasias increases 
with elevation of histopathologic grade of cervical tis-
sues [71]. Number of samples with strong staining for 
galectin-1 increased from low-grade squamous intra-
epithelial lesions to high-grade squamous intraepithelial 
lesions and to invasive squamous cell carcinomas.
Galectin-1 binding inhibitors. (E)-methyl 
2-phenyl-4-(b-D-galactopyranosyl)-but-2-enoate 
15 was shown to be a selective inhibitor of galectin-1 
carbohydrate recognition domain (CRD) with inhibitory 
potency of 313 μM [72]. Divalent carbamate 19, one of 
the 1,4-substituted 1,2,3-triazoles with a Kd value as 
low as 3.2 μM for galectin-1, was described by Tejler 
et al. [73]. There are also other molecules with inhibi-
tory potency for galectin-1 CRD described by different 
groups (not cited due to space restrictions).
Although with most of the binding partners galectin-1 
interacts through its CRD, it is worth mentioning that 
the lectin also interacts with oncogenic form of H-Ras 
(H-Ras(12V)) in complex with GTP, stabilising ancho-
rage of the complex to the membrane and promoting 
oncogenic transformation by activated H-Ras(12V). This 
interaction is blocked by farnesylthiosalicylic acid [74].
CONCLUDING REMARKS
In most of the cases described, galectin-1 is up-
regulated in tumors in comparison to normal tissue. 
Moreover, the presence of the lectin is associated with 
metastases and poor prognosis of disease outcome. 
Taking all above mentioned into account, the use of 
galectin-1 detection for diagnostics of cancer should 
be promoted and use of galectin-1 inhibitors as well 
as siRNA in combination with other antitumor agents 
should be considered. It is necessary to note that  the 
expression of galectin-1 on mRNA level is not always 
accompanied by protein expression [26].
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